Theratechnologies Inc.’s THTX share price has dipped by 16.77%, which has investors questioning if this is right time to buy.

Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) for RN0361-an APOC3 ...

therapeutic for severe hypertriglyceridemia (SHTG), mixed dyslipidemia, and familial chylomicronemia syndrome (FCS) treatment. The company plans to advance RN0361 development in HTG patients based ...

Ionis has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen.

A new framework for the categorization and management of chylomicronemia - an extreme form of hypertriglyceridemia defined as ... individuals with chylomicronemia are categorized as having familial ...

Ionis Pharmaceuticals, Inc. today announced that it has entered into a license agreement under which Sobi® receives exclusive rights in countries outside the U.S., Canada and China to commercialize ...

Ionis Pharmaceuticals has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen intended for familial chylomicronaemia syndrome (FCS ...

an APOC3-targeting treatment being developed for severe hypertriglyceridemia (sHTG) and familial chylomicronemia syndrome (FCS). The company is also pursuing two discovery phase programs ...

This includes familial hypercholesterolemia (high cholesterol), familial hypertriglyceridemia (high triglycerides), and familial combined hyperlipidemia (high levels of both cholesterol and ...